Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Accumulated Depreciation (2023 - 2025)

Historic Accumulated Depreciation for Artiva Biotherapeutics (ARTV) over the last 3 years, with Q3 2025 value amounting to $7.8 million.

  • Artiva Biotherapeutics' Accumulated Depreciation rose 4662.91% to $7.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.8 million, marking a year-over-year increase of 4662.91%. This contributed to the annual value of $5.9 million for FY2024, which is 6769.54% up from last year.
  • Artiva Biotherapeutics' Accumulated Depreciation amounted to $7.8 million in Q3 2025, which was up 4662.91% from $7.2 million recorded in Q2 2025.
  • In the past 5 years, Artiva Biotherapeutics' Accumulated Depreciation registered a high of $7.8 million during Q3 2025, and its lowest value of $3.5 million during Q4 2023.
  • For the 3-year period, Artiva Biotherapeutics' Accumulated Depreciation averaged around $6.0 million, with its median value being $6.2 million (2024).
  • Its Accumulated Depreciation has fluctuated over the past 5 years, first soared by 6769.54% in 2024, then surged by 4662.91% in 2025.
  • Over the past 3 years, Artiva Biotherapeutics' Accumulated Depreciation (Quarter) stood at $3.5 million in 2023, then surged by 67.7% to $5.9 million in 2024, then soared by 31.83% to $7.8 million in 2025.
  • Its last three reported values are $7.8 million in Q3 2025, $7.2 million for Q2 2025, and $6.5 million during Q1 2025.